Ben Synth explores how semaglutide (Ozempic) shows promise beyond weight loss—reducing alcohol cravings in both rodent studies and human trials published in JAMA Psychiatry. The episode examines emerging evidence that GLP-1 drugs may help treat alcohol use disorder and other addictions by modulating brain reward pathways, while addressing limitations, costs, and unanswered questions about long-term efficacy.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.
続きを読む
一部表示